Literature DB >> 23889247

A UK national survey of investigations for beta-lactam hypersensitivity - heterogeneity in practice and a need for national guidelines - on behalf of British Society for Allergy and Clinical Immunology (BSACI).

A G Richter1, S M Nasser, M T Krishna.   

Abstract

BACKGROUND: Beta lactams (BL) are the most widely prescribed antibiotics in the UK and the commonest cause of hypersensitivity reactions. There are no UK guidelines for BL testing and the most relevant guidelines were devised by the European Network for Drug Allergy (ENDA) on behalf of the European Academy of Allergy and Clinical Immunology.
OBJECTIVE: Delivery of allergy services differs across Europe, so this survey was designed to investigate how closely UK practice adhered to these guidelines.
METHODS: An online survey, using surveymonkey.com software, was sent to all consultants offering an allergy service in the UK and who were members of either BSACI or 'Travellers' (Immunology consultant group).
RESULTS: The response rate was 48% (n=81/165) and BL allergy testing was undertaken by 78% of respondents. All responders requested SsIgE, although four responders stated they rarely requested. Skin testing was undertaken by 87% of respondents who perform beta lactam testing with 17% undertaking skin prick testing (SPT) only, 77% SPT followed by intra-dermal testing (IDT) if the former were negative or indeterminate and 6% SPT and IDT in all cases. The drugs, doses and protocols for skin testing varied considerably. Drug provocation testing was undertaken by 87% of respondents who undertake beta lactam testing with significant heterogeneity in protocols. Respondents that investigated ≤ 20 patients per year demonstrated lower adherence to ENDA recommendations compared to those who saw > 20. Following positive testing, 79% advised avoidance of all penicillins only and the remainder advised additional drug avoidance. CONCLUSION AND CLINICAL RELEVANCE: This survey revealed variation in the investigation and management of BL hypersensitivity in the UK with some centres reporting procedures that could potentially put patients at risk of anaphylaxis if allergy was falsely excluded. This survey highlights an urgent need for evidence based national guidelines and standardisation of practice.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  UK; allergy; beta-lactam; cephalosporin; drug provocation test; hypersensitivity; penicillin; serum-specific IgE; skin test; survey

Mesh:

Substances:

Year:  2013        PMID: 23889247     DOI: 10.1111/cea.12134

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  4 in total

Review 1.  The 3 Cs of Antibiotic Allergy-Classification, Cross-Reactivity, and Collaboration.

Authors:  Jason A Trubiano; Cosby A Stone; M Lindsay Grayson; Karen Urbancic; Monica A Slavin; Karin A Thursky; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2017-08-23

2.  The impact of national guidelines on venom immunotherapy practice in the United Kingdom.

Authors:  L Diwakar; P Ewan; P A J Huber; A Clark; S Nasser; M T Krishna
Journal:  Clin Exp Allergy       Date:  2016-05       Impact factor: 5.018

3.  Outcome of drug provocation testing in children with suspected beta-lactam hypersensitivity.

Authors:  Si Hui Goh; Kok Wee Chong; Wen Chin Chiang; Anne Goh; Wenyin Loh
Journal:  Asia Pac Allergy       Date:  2021-01-14

4.  Diagnostic procedures & practices in drug allergy/hypersensitivity: a survey of 13 Asian countries.

Authors:  Min-Moon Tang; Jie Shen Fok; Bernard Yu-Hor Thong; James Yun; Philip Hei Li; Hye-Ryun Kang; Francis Thien; Masao Yamaguchi; Michaela Lucas; Yoon-Seok Chang; Byung-Keun Kim; Mizuho Nagao; Iris Rengganis; Yi-Giien Tsai; Wen-Hung Chung; Ticha Rerkpattanapipat; Wasu Kamchaisatian; Ting Fan Leung; Joo-Yoon Ho; Luo Zhang; Amir Hamzah Abdul Latiff; Takao Fujisawa; Mariana C Castells; Pascal Demoly; Jiu Yao Wang; Ruby Pawankar
Journal:  Asia Pac Allergy       Date:  2020-10-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.